Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

   Completed · Phase 1 · Primary Central Nervous System Lymphoma (PCNSL)

   NCT03703167 · AbbVie Inc. · 1 U.S. investigator

   $512,820research payments

2. A Pivotal Study of the Premia Spine TOPS™ System

   Completed · Not applicable · Lumbar Spinal Stenosis

   NCT03012776 · Premia Spine, Ltd. · 26 U.S. investigators

   $510,229research payments

3. A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

   Recruiting · Phase 2 · Pancreatic Ductal Adenocarcinoma

   NCT05851924 · Ipsen Biopharmaceuticals, Inc · 2 U.S. investigators

   $507,427research payments

4. Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

   Completed · Phase 3 · Irritable Bowel Syndrome With Constipation (IBS-C)

   NCT05643534 · Ardelyx, Inc. · 20 U.S. investigators

   $506,440research payments

5. A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

   Completed · Phase 2 · Metastatic Breast Cancer

   NCT04699630 · Daiichi Sankyo Inc. · 6 U.S. investigators

   $506,346research payments

6. Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

   Completed · Phase 3 · Actinic Keratoses

   NCT05662202 · Biofrontera Inc. · 11 U.S. investigators

   $505,819research payments

7. Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)

   Completed · Phase 3 · Biliary Atresia

   NCT04336722 · Albireo Pharma, Inc. · 25 U.S. investigators

   $504,808research payments

8. Ruptured Aneurysms Treated With Hydrogel Coils

   Status unknown · Ruptured Aneurysm

   NCT03252314 · Microvention, Inc. · 34 U.S. investigators

   $504,284research payments

9. Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

   Recruiting · Phase 1, Phase 2 · ESRD (End-Stage Renal Disease)

   NCT06878560 · United Therapeutics Corporation · 1 U.S. investigator

   $504,246research payments

10. A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

    Completed · Phase 1 · Type 2 Diabetes Mellitus

    NCT06362265 · Eli Lilly and Company · 10 U.S. investigators

    $502,247research payments

11. A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

    Recruiting · Phase 3 · Crohn's Disease

    NCT05995353 · AbbVie Inc. · 12 U.S. investigators

    $500,951research payments

12. National Liver Cancer Screening Trial

    Recruiting · Phase 4 · Carcinoma, Hepatocellular

    NCT06084234 · Fujifilm Healthcare Americas Corporation · 1 U.S. investigator

    $500,000research payments

13. Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)

    Terminated · Phase 3 · Duchenne Muscular Dystrophy

    NCT01247207 · Ptc Therapeutics, Inc. · 27 U.S. investigators

    $498,899research payments

14. A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease

    Active, not recruiting · Phase 1, Phase 2 · Wilson Disease

    NCT04884815 · Ultragenyx Pharmaceutical Inc. · 12 U.S. investigators

    $495,859research payments

15. A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

    Recruiting · Phase 1 · B-cell Non-Hodgkins Lymphoma (B-NHL)

    NCT05685173 · Regeneron Pharmaceuticals, Inc. · 8 U.S. investigators

    $494,085research payments

16. A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

    Completed · Phase 2 · Early-stage Parkinson's Disease

    NCT04658186 · UCB SA · 33 U.S. investigators

    $492,689research payments

17. Registry of Asthma Patients Initiating DUPIXENT®

    Completed · Asthma

    NCT04287621 · Regeneron Pharmaceuticals, Inc. · 58 U.S. investigators

    $492,015research payments

18. A Study of LY3866288 in Healthy Participants

    Completed · Phase 1 · Healthy

    NCT06641037 · Eli Lilly and Company · 1 U.S. investigator

    $491,130research payments

19. Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

    Completed · Phase 2 · Non-small Cell Lung Cancer

    NCT04484142 · Daiichi Sankyo Inc. · 10 U.S. investigators

    $490,628research payments

20. Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

    Completed · Phase 3 · Parkinson's Disease (PD)

    NCT04750226 · AbbVie Inc. · 27 U.S. investigators

    $488,890research payments

21. A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age

    Completed · Phase 3 · SARS-CoV-2

    NCT05436834 · ModernaTX, Inc. · 30 U.S. investigators

    $488,774research payments

22. A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

    Completed · Phase 4 · Psoriasis

    NCT05701995 · E.r. Squibb & Sons, L.l.c. · 32 U.S. investigators

    $488,338research payments

23. Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    Active, not recruiting · Phase 3 · Chronic Lymphocytic Leukemia

    NCT04666038 · Eli Lilly and Company · 21 U.S. investigators

    $487,681research payments

24. EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

    Completed · Phase 1 · Rhabdoid Tumors

    NCT02601937 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $487,207research payments

25. A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

    Active, not recruiting · Phase 3 · Myelofibrosis

    NCT04576156 · Geron Corporation · 11 U.S. investigators

    $484,779research payments

26. HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

    Active, not recruiting · Phase 2 · Non-Small Cell Lung Cancer Metastatic

    NCT04619004 · Daiichi Sankyo Inc. · 15 U.S. investigators

    $483,464research payments

27. Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

    Completed · Phase 3 · Follicular Lymphoma

    NCT02947347 · AbbVie Inc. · 23 U.S. investigators

    $482,058research payments

28. Alzheimer's Disease Neuroimaging Initiative 4

    Enrolling by invitation · Mild Cognitive Impairment

    NCT05617014 · Life Molecular Imaging Ltd · 1 U.S. investigator

    $481,650research payments

29. Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

    Active, not recruiting · Phase 3 · Breast Neoplasm

    NCT05169567 · Eli Lilly and Company · 22 U.S. investigators

    $480,599research payments

30. Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

    Active, not recruiting · Phase 1 · Diffuse Large B-Cell Lymphoma

    NCT05618028 · AbbVie Inc. · 12 U.S. investigators

    $478,874research payments

31. Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

    Active, not recruiting · Phase 3 · Crohn's Disease

    NCT06332534 · AbbVie Inc. · 15 U.S. investigators

    $478,556research payments

32. A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

    Active, not recruiting · Phase 2 · Ulcerative Colitis

    NCT06975722 · Sanofi US Services Inc. · 19 U.S. investigators

    $477,132research payments

33. A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

    Active, not recruiting · Phase 2 · Cytomegalovirus Infection

    NCT05683457 · ModernaTX, Inc. · 3 U.S. investigators

    $476,474research payments

34. IT Matters: The Erectile Restoration Registry

    Enrolling by invitation · Erectile Dysfunction

    NCT04200937 · Boston Scientific Corporation · 22 U.S. investigators

    $475,940research payments

35. Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

    Completed · Phase 3 · Prostate Cancer

    NCT05605964 · Sumitomo Pharma America, Inc. · 43 U.S. investigators

    $475,186research payments

36. A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

    Recruiting · Phase 1 · Advanced Solid Tumors

    NCT06880549 · ModernaTX, Inc. · 3 U.S. investigators

    $474,078research payments

37. A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

    Terminated · Phase 1 · Non-Small Cell Lung Cancer

    NCT06685718 · Beone Medicines USA, Inc. · 5 U.S. investigators

    $474,066research payments

38. Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

    Terminated · Phase 2, Phase 3 · Irritability Associated With Autism Spectrum Disorder

    NCT05555615 · Acadia Pharmaceuticals Inc · 19 U.S. investigators

    $470,947research payments

39. TAS102 in Combination With NAL-IRI in Advanced GI Cancers

    Active, not recruiting · Phase 1, Phase 2 · Colorectal Adenocarcinoma

    NCT03368963 · Ipsen Biopharmaceuticals, Inc · 2 U.S. investigators

    $469,477research payments

40. A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

    Completed · Phase 3 · Schizophrenia

    NCT04092686 · Sumitomo Pharma America, Inc. · 2 U.S. investigators

    $469,010research payments

41. A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

    Recruiting · Phase 1 · Advanced Solid Tumor

    NCT06625593 · Beone Medicines USA, Inc. · 6 U.S. investigators

    $467,543research payments

42. A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

    Completed · Phase 2 · Alzheimer's Disease

    NCT04867616 · UCB SA · 18 U.S. investigators

    $467,527research payments

43. A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

    Terminated · Phase 1 · Solid Tumors

    NCT06158958 · AbbVie Inc. · 12 U.S. investigators

    $467,527research payments

44. Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

    Active, not recruiting · Phase 3 · Alagille Syndrome

    NCT05035030 · Albireo Pharma, Inc. · 11 U.S. investigators

    $467,094research payments

45. A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

    Active, not recruiting · Phase 1, Phase 2 · Advanced Solid Tumor

    NCT05081609 · Ascendis Pharma Endocrinology Inc · 11 U.S. investigators

    $465,478research payments

46. A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

    Active, not recruiting · Phase 1 · Solid Tumor

    NCT04419532 · Daiichi Sankyo Inc. · 1 U.S. investigator

    $464,148research payments

47. A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

    Active, not recruiting · Phase 3 · Ulcerative Colitis (UC)

    NCT03398135 · AbbVie Inc. · 36 U.S. investigators

    $463,246research payments

48. A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

    Active, not recruiting · Phase 3 · Fabry Disease

    NCT05206773 · Genzyme Corporation · 15 U.S. investigators

    $460,956research payments

49. Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

    Recruiting · Phase 3 · Non-small Cell Lung Cancer

    NCT06899126 · Daiichi Sankyo Inc. · 15 U.S. investigators

    $460,411research payments

50. Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

    Completed · Phase 4 · Moderate-to-Severe Atopic Dermatitis

    NCT05590585 · Regeneron Pharmaceuticals, Inc. · 18 U.S. investigators

    $454,981research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.